{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:59:43Z","timestamp":1764079183359},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Jingzhou Central Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12253-016-0097-y","type":"journal-article","created":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T23:05:36Z","timestamp":1470870336000},"page":"307-315","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance"],"prefix":"10.1007","volume":"23","author":[{"given":"Jinfeng","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"issue":"Suppl 1","key":"97_CR1","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"AF Gazdar","year":"2009","unstructured":"Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl 1):S24\u2013S31. doi: 10.1038\/onc.2009.198","journal-title":"Oncogene"},{"issue":"2","key":"97_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ijc.21496","volume":"118","author":"H Shigematsu","year":"2006","unstructured":"Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118(2):257\u2013262. doi: 10.1002\/ijc.21496","journal-title":"Int J Cancer"},{"key":"97_CR3","doi-asserted-by":"publisher","unstructured":"Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang PC (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9 (2):154-162. doi: 10.1097\/JTO.0000000000000033","DOI":"10.1097\/JTO.0000000000000033"},{"issue":"16","key":"97_CR4","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","volume":"290","author":"MG Kris","year":"2003","unstructured":"Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16):2149\u20132158. doi: 10.1001\/jama.290.16.2149","journal-title":"JAMA"},{"issue":"2","key":"97_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials G","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials G (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123\u2013132. doi: 10.1056\/NEJMoa050753","journal-title":"N Engl J Med"},{"issue":"14","key":"97_CR6","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","volume":"11","author":"AJ Barker","year":"2001","unstructured":"Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L (2001) Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11(14):1911\u20131914","journal-title":"Bioorg Med Chem Lett"},{"issue":"20","key":"97_CR7","first-page":"5749","volume":"62","author":"AE Wakeling","year":"2002","unstructured":"Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62(20):5749\u20135754","journal-title":"Cancer Res"},{"issue":"12","key":"97_CR8","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol Off J Am Soc Clin Oncol 21(12):2237\u20132246. doi: 10.1200\/JCO.2003.10.038","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"97_CR9","doi-asserted-by":"publisher","unstructured":"Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 22 (16):3238-3247. doi: 10.1200\/JCO.2004.11.057","DOI":"10.1200\/JCO.2004.11.057"},{"issue":"19","key":"97_CR10","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","volume":"12","author":"T Kosaka","year":"2006","unstructured":"Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T (2006) Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non\u2013Small Cell Lung Cancer and Acquired Resistance to Gefitinib. Clin Cancer Res 12(19):5764\u20135769","journal-title":"Clin Cancer Res"},{"issue":"21","key":"97_CR11","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","volume":"12","author":"MN Balak","year":"2006","unstructured":"Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W (2006) Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor\u2013Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clin Cancer Res 12(21):6494\u20136501","journal-title":"Clin Cancer Res"},{"key":"97_CR12","doi-asserted-by":"crossref","unstructured":"Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong, K K (2008) BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27 (34):4702-4711. doi: http:\/\/www.nature.com\/onc\/journal\/v27\/n34\/suppinfo\/onc2008109s1.html","DOI":"10.1038\/onc.2008.109"},{"issue":"2","key":"97_CR13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. J Pharmacol Exp Ther 343(2):342\u2013350","journal-title":"J Pharmacol Exp Ther"},{"issue":"21","key":"97_CR14","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.0502860102","volume":"102","author":"EL Kwak","year":"2005","unstructured":"Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102(21):7665\u20137670","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"97_CR15","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2012.45.0981","volume":"31","author":"N Katakami","year":"2013","unstructured":"Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N (2013) LUX-Lung 4: a phase ii trial of afatinib in patients with advanced non\u2013small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31(27):3335\u20133341","journal-title":"J Clin Oncol"},{"issue":"24","key":"97_CR16","doi-asserted-by":"publisher","first-page":"7808","DOI":"10.1158\/1078-0432.ccr-11-1712","volume":"17","author":"K Taniguchi","year":"2011","unstructured":"Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, Higashiyama M, Kodama K, Imamura F, Kato K (2011) Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas. Clin Cancer Res 17(24):7808\u20137815. doi: 10.1158\/1078-0432.ccr-11-1712","journal-title":"Clin Cancer Res"},{"issue":"9","key":"97_CR17","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz Jr LA (2008) Circulating mutant DNA to assess tumor dynamics. Nature Medicine 14 (9):985-990. http:\/\/www.nature.com\/nm\/journal\/v14\/n9\/suppinfo\/nm.1789_S1.html","journal-title":"Nature Medicine"},{"issue":"2","key":"97_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","volume":"28","author":"D Jackman","year":"2010","unstructured":"Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, Lynch T, Johnson BE, Miller VA (2010) Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(2):357\u2013360. doi: 10.1200\/JCO.2009.24.7049","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"97_CR19","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","volume":"20","author":"GR Oxnard","year":"2014","unstructured":"Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, J\u00e4nne PA (2014) Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA. Clin Cancer Res 20(6):1698\u20131705","journal-title":"Clin Cancer Res"},{"issue":"15","key":"97_CR20","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-14-2151","volume":"21","author":"M Watanabe","year":"2015","unstructured":"Watanabe M, Kawaguchi T, S-I I, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Sakamoto K, Matsumura A, Koh Y (2015) Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non\u2013Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clin Cancer Res 21(15):3552\u20133560","journal-title":"Clin Cancer Res"},{"issue":"4","key":"97_CR21","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.18632\/oncotarget.3041","volume":"6","author":"E Kidess","year":"2015","unstructured":"Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, Wiedenmann B, Norton JA, Lee M, Jeffrey SS (2015) Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget 6(4):2549","journal-title":"Oncotarget"},{"issue":"3","key":"97_CR22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/bjc.2015.225","volume":"113","author":"A Szpechcinski","year":"2015","unstructured":"Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, Kupis W, Rudzinski P, Langfort R, Puscinska E, Bielen P, Sliwinski P, Orlowski T (2015) Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer 113(3):476\u2013483. doi: 10.1038\/bjc.2015.225","journal-title":"Br J Cancer"},{"key":"97_CR23","doi-asserted-by":"publisher","first-page":"20913","DOI":"10.1038\/srep20913","volume":"6","author":"D Zheng","year":"2016","unstructured":"Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, Zhang HP, Zhang L, Luo J, Zhang J, Tang L, Su B, Chen G, Zhu G, Gu Y, Xu JF (2016) Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Report 6:20913. doi: 10.1038\/srep20913","journal-title":"Sci Report"},{"issue":"16","key":"97_CR24","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2008.17.3930","volume":"27","author":"H Bai","year":"2009","unstructured":"Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J (2009) Epidermal growth factor receptor mutations in plasma dna samples predict tumor response in chinese patients with stages iiib to iv non\u2013small-cell lung cancer. J Clin Oncol 27(16):2653\u20132659","journal-title":"J Clin Oncol"},{"issue":"6","key":"97_CR25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/sj.bjc.6603949","volume":"97","author":"H Kimura","year":"2007","unstructured":"Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M, Nakao S (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97(6):778\u2013784. doi: 10.1038\/sj.bjc.6603949","journal-title":"Br J Cancer"},{"issue":"3","key":"97_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.lungcan.2015.10.004","volume":"90","author":"KS Thress","year":"2015","unstructured":"Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett JC (2015) EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90(3):509\u2013515. doi: 10.1016\/j.lungcan.2015.10.004","journal-title":"Lung Cancer"},{"issue":"7511","key":"97_CR27","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/511524a","volume":"511","author":"E Yong","year":"2014","unstructured":"Yong E (2014) Cancer biomarkers: Written in blood. Nature 511(7511):524\u2013526. doi: 10.1038\/511524a","journal-title":"Nature"},{"issue":"1","key":"97_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lungcan.2015.01.013","volume":"88","author":"J De Gr\u00e8ve","year":"2015","unstructured":"De Gr\u00e8ve J, Moran T, Graas M-P, Galdermans D, Vuylsteke P, Canon J-L, Schallier D, Decoster L, Teugels E, Massey D, Chand VK, Vansteenkiste J (2015) Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer 88(1):63\u201369. doi: 10.1016\/j.lungcan.2015.01.013","journal-title":"Lung Cancer"},{"key":"97_CR29","doi-asserted-by":"crossref","unstructured":"Bar J, Botser D, Navon R, Peled N, Biran H, Gal-Yam EN, Ben-Arieh S, Raskin S, Onn A A Single-arm phase II study of afatinib treatment for advanced EGFR-mutant non-small cell lung cancer (mNSCLC) patients (pts) with EGFR-tyrosine kinase inhibitor (TKI) resistance. In: ASCO Annual Meeting Proceedings, 2015. vol 15_suppl. p e19031","DOI":"10.1200\/jco.2015.33.15_suppl.e19031"},{"key":"97_CR30","doi-asserted-by":"publisher","unstructured":"Lee JY, Sun JM, Lim SH, Kim HS, Yoo KH, Jung KS, Song HN, Ku BM, Koh J, Bae YH, Lee SH, Ahn JS, Park K, Ahn MJ (2016) A phase Ib\/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib. Clin Cancer Res 22(9):2139\u20132145. doi: 10.1158\/1078-0432.CCR-15-1653","DOI":"10.1158\/1078-0432.CCR-15-1653"},{"issue":"8","key":"97_CR31","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.18632\/oncotarget.3332","volume":"6","author":"S Zhang","year":"2015","unstructured":"Zhang S, Zheng X, Huang H, Wu K, Wang B, Chen X, Ma S (2015) Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget 6(8):5832","journal-title":"Oncotarget"},{"issue":"4","key":"97_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1056\/NEJMoa0800668","volume":"359","author":"S Maheswaran","year":"2008","unstructured":"Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359(4):366\u2013377. doi: 10.1056\/NEJMoa0800668","journal-title":"N Engl J Med"},{"issue":"1","key":"97_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","volume":"1","author":"ES Kim","year":"2011","unstructured":"Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44\u201353. doi: 10.1158\/2159-8274.CD-10-0010","journal-title":"Cancer Discov"},{"key":"97_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1155\/2015\/809835","volume":"2015","author":"AP Jekunen","year":"2015","unstructured":"Jekunen AP (2015) Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol 2015:11. doi: 10.1155\/2015\/809835","journal-title":"J Oncol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-016-0097-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-016-0097-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-016-0097-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-016-0097-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T11:44:37Z","timestamp":1568288677000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-016-0097-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1007\/s12253-016-0097-y","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,11]]}}}